Phase 3 study of REOLYSIN in combination with paclitaxel, for the treatment of hormone receptor positive, HER2 receptor negative (HR+/HER2-) metastatic breast cancer (mBC) patients.

Trial Profile

Phase 3 study of REOLYSIN in combination with paclitaxel, for the treatment of hormone receptor positive, HER2 receptor negative (HR+/HER2-) metastatic breast cancer (mBC) patients.

Planning
Phase of Trial: Phase III

Latest Information Update: 10 May 2018

At a glance

  • Drugs Pelareorep (Primary) ; Paclitaxel
  • Indications Advanced breast cancer
  • Focus Registrational; Therapeutic Use
  • Sponsors Oncolytics Biotech
  • Most Recent Events

    • 10 May 2018 According to an Oncolytics Biotech media release, the company has reached an agreement with the U.S. Food and Drug Administration (FDA) under a Special Protocol Assessment (SPA) for the protocol design, clinical endpoints and statistical analysis approach for the company's phase 3 study evaluating pelareorep for the treatment of metastatic breast cancer
    • 09 Mar 2018 Planned number of patients changed from 400 to 450, according to an Oncolytics Biotech media release.
    • 09 Mar 2018 According to an Oncolytics Biotech media release, company has discussed about this study at the End-of-Phase 2 meeting with the FDA, with subsequent increase in the planned patient No to 450. Also, company received a Final Advice Letter from the EMA suggesting that this study is basis of a Marketing Authorization Application (MAA) in Europe.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top